The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …

Abstract Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized
cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …

Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

The Chimera antigen receptor (CAR)-T cell therapy has gained great success in the clinic.
However, there are still major challenges for its wider applications in a variety of cancer …

Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …

The derivation of induced pluripotent stem cells (iPSCs) over a decade ago sparked
widespread enthusiasm for the development of new models of human disease, enhanced …

Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements
results in antitumor treatments, especially against hematological malignancies, where it …